Prometheus Research appoints vp of sales

Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.

Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.

Harker takes responsibility for developing and managing sales for the company's Research Informatics biomedical software services and new HTSQL database software for industry.

Prior to joining Prometheus, Harker held a variety of sales roles, most recently as managing director for BondDesk, a provider of software and services for fixed income trading.






You may also like

Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Digital

AstraZeneca launches online direct-to-consumer platform to expand US patient access to medications

AstraZeneca Direct is a digital platform offering eligible US patients convenient home delivery of prescriptions such as AIRSUPRA, FARXIGA and FLUMIST
Finance

New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem

eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia
Finance

Pfizer to acquire Metsera in $4.9bn deal, expanding obesity drug pipeline with next-generation incretin and amylin therapies

The deal strengthens Pfizer’s position in the fast-growing obesity market, with additional milestone payments of up to $2.3bn tied to key clinical and regulatory achievements
Finance

DaltonTx secures £4m in seed financing to build adaptive, AI-enabled discovery platforms

The UK-based technology company's adaptive platform will plug directly into pharma, biotech and CRO workflows, giving teams instant access to AI-enabled discovery
Manufacturing

Prange Pharma to acquire MSD Animal Health manufacturing site in Aprilia, Italy

Following completion, the site will relaunch as Aprilia Animal Health, focussing on contract manufacturing of animal health products whilst preserving jobs and expanding European expertise
Finance

EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform

The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio
Subscribe now